Drug intelligence / Profile preview

Maxing Huoqiao Granules

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Maxing Huoqiao Granules (MXHQ) is a Traditional Chinese Medicine (TCM) formula presented in granule form. Developed and manufactured by Jiangyin Tianjiang Pharmaceutical Co., Ltd., a prominent producer of TCM herbal extract granules, it is currently undergoing clinical investigation for the treatment of non-severe community-acquired pneumonia. TCM formula granules are produced through a modern process involving extraction, concentration, drying, and granulation, aiming to provide a standardized, stable, safe, and convenient alternative to traditional herbal decoctions.

Other names: MXHQ granules麻杏藿翘颗粒

Targets

ISG15 (Interferon-stimulated gene 15 protein)PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on Maxing Huoqiao Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxing Huoqiao Granules.

Explore the full profile